Sofinnova, Polaris lead CHF 54m series-A for Noema
Sofinnova Partners and Polaris Partners have co-led a CHF 54m series-A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders.
More on Early-stage
Forbion et al. in $196m round for NewAmsterdam Pharma
Company intends to use the fresh capital to finance the full phase-III development of its obicetrapib drug
Element Ventures leads €15.5m funding for fintech Minna
New funding takes the total the company has raised so far to €23m
EQT Ventures leads $18m round for Sana Labs
Latest round brings its total funding so far to $23m, having previously raised $4m in 2018 and $1m in 2017
HBM Healthcare leads €127m series-B for IO Biotech
Funding follows the US Food and Drug Administration granting the company breakthrough therapy designation for its lead programmes
Latest News
Fidelium Partners acquires RET
Parent company Reiff Group said in a statement that the sale is part of its ongoing realignment plan
Star Capital acquires Rail Operations
Neil Bennett, previously of Beacon Rail Leasing, will be appointed executive chairman of the company
Heal Capital closes debut fund on €100m
Healthtech-focused VC sees oppprtunities in the developing European market, managing director Christian Weiß tells Unquote
Mobeus invests in Northern Bloc
Paul Keen, previously CFO of ETC Venues, will join the board as a non-executive director